These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27207883)

  • 1. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.
    Iehara T; Yagyu S; Tsuchiya K; Kuwahara Y; Miyachi M; Tajiri T; Sugimoto T; Sawada T; Hosoi H
    Jpn J Clin Oncol; 2016 Jul; 46(7):661-6. PubMed ID: 27207883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.
    Amano H; Uchida H; Tanaka Y; Tainaka T; Mori M; Oguma E; Kishimoto H; Kawashima H; Arakawa Y; Hanada R; Koh K
    J Pediatr Surg; 2018 Sep; 53(9):1761-1765. PubMed ID: 29195808
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multivariate analysis of risk factors for patients with stage 4 neuroblastoma who were older than 18 months at diagnosis: a report from a single institute in Shanghai, China.
    Cai J; Pan C; Tang Y; Chen J; Zhou M; Li B; Xue H; Shen S; Gao Y; Zhang A; Tang J
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1327-1335. PubMed ID: 28283783
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic neuroblastoma: low mortality and high morbidity.
    Cruccetti A; Kiely EM; Spitz L; Drake DP; Pritchard J; Pierro A
    J Pediatr Surg; 2000 May; 35(5):724-8. PubMed ID: 10813335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comprehensive protocol for diagnosis and treatment of childhood neuroblastoma--results of 45 cases].
    Tang JY; Pan C; Chen J; Xu M; Chen J; Xue HL; Gu LJ; Dong R; Ye H; Zhou M; Wang YP
    Zhonghua Er Ke Za Zhi; 2006 Oct; 44(10):770-3. PubMed ID: 17229383
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of minimal residual disease detection prior to autologous stem cell transplantation for post-transplant outcome in high risk neuroblastoma.
    Bochennek K; Esser R; Lehrnbecher T; Glienke W; Wehner S; Erben S; Soerensen J; Schwabe D; Bader P; Klingebiel T; Koehl U
    Klin Padiatr; 2012 Apr; 224(3):139-42. PubMed ID: 22377741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of image-defined risk factors, tumor resectability, and prognosis in children with localized neuroblastoma.
    Zhang AA; Pan C; Xu M; Wang XX; Ye QD; Gao YJ; Tang JY
    World J Pediatr; 2019 Dec; 15(6):572-579. PubMed ID: 31342464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The significance of serial histopathology in a residual mass for outcome of intermediate risk stage 3 neuroblastoma.
    Marachelian A; Shimada H; Sano H; Jackson H; Stein J; Sposto R; Matthay KK; Baker D; Villablanca JG
    Pediatr Blood Cancer; 2012 May; 58(5):675-81. PubMed ID: 22493777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The treatment of neuroblastoma with intraspinal extension with chemotherapy followed by surgical removal of residual disease. A prospective study of 42 patients--results of the NBL 90 Study of the French Society of Pediatric Oncology.
    Plantaz D; Rubie H; Michon J; Mechinaud F; Coze C; Chastagner P; Frappaz D; Gigaud M; Passagia JG; Hartmann O
    Cancer; 1996 Jul; 78(2):311-9. PubMed ID: 8674009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy.
    Kushner BH; Cheung NK; LaQuaglia MP; Ambros PF; Ambros IM; Bonilla MA; Gerald WL; Ladanyi M; Gilbert F; Rosenfield NS; Yeh SD
    J Clin Oncol; 1996 Feb; 14(2):373-81. PubMed ID: 8636746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease.
    Simon T; Hero B; Bongartz R; Schmidt M; Müller RP; Berthold F
    Strahlenther Onkol; 2006 Jul; 182(7):389-94. PubMed ID: 16826357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does megatherapy contribute to survival in metastatic neuroblastoma? A retrospective analysis. German Cooperative Neuroblastoma Study Group.
    Hero B; Kremens B; Klingebiel T; Bender-Götze C; Burdach S; Schrappe M; Berthold F
    Klin Padiatr; 1997; 209(4):196-200. PubMed ID: 9293450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimal residual disease is a prognostic marker for neuroblastoma with bone marrow infiltration.
    Cai JY; Pan C; Tang YJ; Chen J; Ye QD; Zhou M; Xue H; Tang JY
    Am J Clin Oncol; 2012 Jun; 35(3):275-8. PubMed ID: 21537148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy.
    Matthay KK; Sather HN; Seeger RC; Haase GM; Hammond GD
    J Clin Oncol; 1989 Feb; 7(2):236-44. PubMed ID: 2915240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results for 79 patients with neuroblastoma detected through mass screening at 6 months of age in a single institute.
    Nishio N; Mimaya J; Nara T; Takashima Y; Horikoshi Y; Urushihara N; Hasegawa S; Aoki K; Hamasaki M
    Pediatr Int; 2006 Dec; 48(6):531-5. PubMed ID: 17168969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age.
    Cheung NK; Kushner BH; Cheung IY; Kramer K; Canete A; Gerald W; Bonilla MA; Finn R; Yeh SJ; Larson SM
    J Clin Oncol; 1998 Sep; 16(9):3053-60. PubMed ID: 9738575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salvage rates after progression of high-risk neuroblastoma with a soft tissue mass.
    Murphy JM; Lim II; Farber BA; Heaton TE; Basu EM; Roberts SS; Modak S; Kushner BH; LaQuaglia MP
    J Pediatr Surg; 2016 Feb; 51(2):285-8. PubMed ID: 26651282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of complete excision on stage III neuroblastoma: a report of the European Neuroblastoma Study Group.
    Powis MR; Imeson JD; Holmes SJ
    J Pediatr Surg; 1996 Apr; 31(4):516-9. PubMed ID: 8801303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable Local Control From Consolidative Radiation Therapy in High-Risk Neuroblastoma Despite Gross Residual Disease, Positive Margins, or Nodal Involvement.
    Ferris MJ; Danish H; Switchenko JM; Deng C; George BA; Goldsmith KC; Wasilewski KJ; Cash WT; Khan MK; Eaton BR; Esiashvili N
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):806-812. PubMed ID: 28244417
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.